AR
HRMY icon

Advisory Research’s Harmony Biosciences HRMY Stock Holding History

Advisory Research’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-43,430
Closed -$2.12M – 372
2022
Q2 		$2.12M Sell
43,430
-240
-0.5% -$10.8K 0.21% 80
2022
Q1 		$2.12M Buy
43,670
+12,500
+40% +$510K 0.17% 95
2021
Q4 		$1.33M Sell
31,170
-87,880
-74% -$3.5M 0.1% 171
2021
Q3 		$4.56M Buy
+119,050
New +$3.83M 0.29% 89

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Advisory Research's HRMY Position: Q3 2022 in Review

Advisory Research sold out of Harmony Biosciences (HRMY) in Q3 2022, closing a stake of 43,430 shares — an estimated $2.12M sold.

Advisory Research first reported a position in HRMY in Q3 2021 and held it in 4 quarters. The position peaked at $4.56M in Q3 2021. 203 funds tracked by Wall St. Rank hold HRMY as of Q3 2022.

  • Advisory Research reported no remaining Harmony Biosciences position as of Q3 2022 after selling out during the quarter.
  • Advisory Research sold 43,430 Harmony Biosciences shares in Q3 2022, an estimated $2.12M.
  • Advisory Research first reported a position in Harmony Biosciences in Q3 2021 and held it in 4 quarters.
  • Advisory Research's Harmony Biosciences position peaked at $4.56M in Q3 2021.
  • 203 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2022.

Based on Advisory Research's 13F filing for Q3 2022, filed 15 Nov 2022.